The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | Overcoming the challenge of resistance to targeted therapies in CLL
Thomas J Kipps, MD, PhD, UC San Diego, Moores Cancer Center, La Jolla, CA, discusses the importance of better identifying mechanisms of resistance to targeted therapies in chronic lymphocytic leukemia (CLL), and how novel agents aim to overcome this challenge. Dr Kipps further explains how next-generation Bruton’s tyrosine kinase (BTK) inhibitors, such as acalabrutinib and zanubrutinib, have shown promise in this space, and highlights the importance of finding the best combination strategies to treat patients. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
